| # | Title | Journal | Year | Citations |
|---|
| 1 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer | New England Journal of Medicine | 2012 | 3,020 |
| 2 | Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer | New England Journal of Medicine | 2013 | 2,723 |
| 3 | Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib | New England Journal of Medicine | 2015 | 2,240 |
| 4 | Reduction Potentials of One-Electron Couples Involving Free Radicals in Aqueous Solution | Journal of Physical and Chemical Reference Data | 1989 | 1,856 |
| 5 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma | New England Journal of Medicine | 2013 | 1,648 |
| 6 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma | New England Journal of Medicine | 2014 | 1,572 |
| 7 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial | Lancet, The | 2016 | 1,570 |
| 8 | Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data | Lancet Oncology, The | 2010 | 1,532 |
| 9 | Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial | Lancet Oncology, The | 2011 | 1,407 |
| 10 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial | Lancet Oncology, The | 2014 | 1,237 |
| 11 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making | Annals of Oncology | 2012 | 1,233 |
| 12 | The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials | Lancet Oncology, The | 2013 | 1,141 |
| 13 | Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis | Lancet, The | 2006 | 967 |
| 14 | Antioxidant activities of carotenes and xanthophylls | FEBS Letters | 1996 | 831 |
| 15 | Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer | Journal of Clinical Oncology | 2010 | 812 |
| 16 | Imaging biomarker roadmap for cancer studies | Nature Reviews Clinical Oncology | 2017 | 792 |
| 17 | Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: Progress, pitfalls, and prospects | Free Radical Biology and Medicine | 2007 | 752 |
| 18 | Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma | Journal of Clinical Oncology | 2013 | 720 |
| 19 | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial | Lancet Oncology, The | 2015 | 661 |
| 20 | Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection | New England Journal of Medicine | 2011 | 624 |
| 21 | A method to measure the duration of DNA syntheses and the potential doubling time from a single sample | Cytometry | 1985 | 597 |
| 22 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial | Lancet Oncology, The | 2013 | 580 |
| 23 | Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial | Lancet, The | 1997 | 563 |
| 24 | Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy | International Journal of Radiation Biology | 2006 | 561 |
| 25 | Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms | Oncogene | 2003 | 530 |
| 26 | Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study | Radiotherapy and Oncology | 2016 | 527 |
| 27 | Low-dose hypersensitivity: current status and possible mechanisms | International Journal of Radiation Oncology Biology Physics | 2001 | 508 |
| 28 | Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) | International Journal of Gynecological Cancer | 2011 | 500 |
| 29 | Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature | Cancer Research | 1997 | 490 |
| 30 | A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer | Radiotherapy and Oncology | 1997 | 469 |
| 31 | Osteoinduction of bone grafting materials for bone repair and regeneration | Bone | 2015 | 469 |
| 32 | Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial | Radiotherapy and Oncology | 1999 | 461 |
| 33 | Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use | European Urology | 2016 | 454 |
| 34 | Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer | Radiotherapy and Oncology | 2012 | 445 |
| 35 | Stereotactic body radiotherapy for oligometastases | Lancet Oncology, The | 2013 | 436 |
| 36 | Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial | Lancet, The | 2005 | 428 |
| 37 | Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions | Journal of Magnetic Resonance Imaging | 2002 | 415 |
| 38 | Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients | International Journal of Radiation Oncology Biology Physics | 2008 | 396 |
| 39 | Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial | Lancet Oncology, The | 2014 | 392 |
| 40 | Studies of bystander effects in human fibroblasts using a charged particle microbeam | International Journal of Radiation Biology | 1998 | 387 |
| 41 | Assessment of Primary Colorectal Cancer Heterogeneity by Using Whole-Tumor Texture Analysis: Contrast-enhanced CT Texture as a Biomarker of 5-year Survival | Radiology | 2013 | 384 |
| 42 | Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial | Lancet Oncology, The | 2016 | 380 |
| 43 | Chemical Radiosensitizers for Use in Radiotherapy | Clinical Oncology | 2007 | 369 |
| 44 | Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I) | British Journal of Cancer | 2010 | 348 |
| 45 | Revised U.K. guidelines for the management of cutaneous melanoma 2010 | British Journal of Dermatology | 2010 | 343 |
| 46 | Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) | European Urology | 2015 | 340 |
| 47 | Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy | British Journal of Radiology | 1993 | 330 |
| 48 | Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging | Journal of Clinical Oncology | 2003 | 328 |
| 49 | Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker | Radiology | 2011 | 328 |
| 50 | Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013 | Annals of Oncology | 2015 | 327 |
